Company news
Silo Pharma, Inc. news in 2023
Silo Pharma, Inc.'s news releases, calls and decks from 2023, newest first.
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
December 27, 2023
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
November 20, 2023
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
November 7, 2023
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
October 15, 2023
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
October 10, 2023
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
September 19, 2023
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
September 11, 2023
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management
August 9, 2023
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders
August 7, 2023
Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers
June 23, 2023
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
June 20, 2023
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
June 12, 2023
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
June 1, 2023
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
May 29, 2023
Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
May 8, 2023
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
April 18, 2023
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
March 26, 2023
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
March 14, 2023
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
February 12, 2023
Silo Pharma Announces Expansion of Intellectual Property Portfolio
February 1, 2023
Silo Pharma Announces Stock Repurchase Program
January 30, 2023
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
January 9, 2023